Skip to Main Navigation
Skip to Page Content

Testing Status of AZT transplacental carcinogenesis study M990048


CASRN: 30516-87-1

Formula: C10-H13-N5-O4

Synonyms/Common Names

  • 3'-Azido-3'-deoxythymidine
  • AZT Transplacental Carcinogenesis Study (AIDS Initiative)

Known Uses

Chemotherapeutic agent. Special study involving in utero exposure using AZT

Chemical Properties

Toxicity Effects (HSDB)

Long-Term Carcinogenicity

  • 19 months (In Utero)  (C99022)  Completed 
    • TR-522 (NIH Number: 06-4458)  (Peer Review Approval 12/09/2004A )
      Toxicology and Carcinogenesis Studies of Transplacental AZT (CASRN 30516-87-1) in Swiss (CD-1®) Mice (in utero Studies)
    • Mice: Swiss CD-1
    • Carcinogenesis Results
      • Male Mice Clear Evidence 
      • Female Mice No Evidence 
    • Dose: AZT: 50, 100, 200, OR 300 MG/KG/DAY; 25, 25, 36, OR 46 PER GROUP.

Special Studies

  • Toxicokinetic Study (Dosed-Water; Intravenous)  (S0874)  Completed 
    • Citation: Transplacental Pharmacokinetics of 3'azido-3'-deoxythymidine (AZT) in CD-1 Mice Toxicokinetic Study Report. November 30, 2006.
    • Female Mice: SWISS CD-1